Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06976268 · ClinicalTrials.gov registry record · Phase 2
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
A Phase 2 study of Parkinson Disease, sponsored by Biohaven Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 550
- Enrollment target
- 15
- Study locations
NCT06976268: Recruiting Phase 2 study of Parkinson Disease, sponsored by Biohaven Therapeutics.
NCT06976268 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Biohaven Therapeutics. The registered enrollment target is 550 participants, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (90% lower). The trial reports 15 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06976268, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Biohaven Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 550 participants
- Enrollment target
- 15
- Study locations
Study Summary
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Primary Outcome
To evaluate the efficacy of BHV-8000 compared to placebo. This objective is measured by assessing the time to prespecified worsening on MDS-UPDRS Part II (motor experiences of daily living per self-administered questionnaire). MDS-UPDRS Part II is a 52-point scale with a higher total score representing more severe disability.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BHV-8000
Study Locations (15)
Florida
- Site-038 - Atlantis
- Site-017 - Boca Raton
- Site-051 - Maitland
Connecticut
- Site-031 - Farmington
- Site-028 - New Haven
Alabama
- Site-049 - Birmingham
California
- Site-041 - Los Angeles
Illinois
- Site-027 - Chicago
Massachusetts
- Site-071 - Boston
Michigan
- Site-015 - Farmington Hills
Missouri
- Site-044 - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06976268 shows while recruiting
NCT06976268 is an interventional study that assigns participants to a tested intervention. The registered 550 participants enrollment target is mid-sized for trials with a published cap, below the 5,325-participant average among 297 other Parkinson Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06976268 lists 15 locations in 12 states (Florida, Connecticut, Alabama).
Frequently Asked Questions
What is clinical trial NCT06976268 about?
NCT06976268 is a clinical study titled "A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease". A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
What is the current status of trial NCT06976268?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 550 participants. The study started on 2025-05-28. Estimated completion is 2027-09.
What conditions does trial NCT06976268 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06976268?
The interventions under investigation include: Placebo (DRUG), BHV-8000 (DRUG).
Who is sponsoring clinical trial NCT06976268?
This trial is sponsored by Biohaven Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06976268 being conducted?
This trial has 15 study locations across Alabama, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06976268's enrollment target sits among peer trials
550 21st of 297 higher than 277 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01852448 · 550 participants
Genetics of Insulin and Incretins in Cystic Fibrosis
- NCT02995252 · 550 participants
The HOPE Study: Characterizing Patients With Hepatitis B and C
- NCT03474913 · 550 participants
Upright MRI for Prostate Cancer Screening
- NCT04761120 · 550 participants
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI